
    
      This is a phase 3b, multicenter, randomized, double-blind, 2-period, 2-sequence crossover
      study in adults with RA or PsA who are naive to etanercept. The study will evaluate injection
      site pain associated with the commercial formulation of etanercept and the new formulation of
      etanercept immediately after injection of each formulation.The study will consist of a
      screening period of up to 14 days, a 2 week treatment period with a 30 day post treatment
      safety follow-up. Each dose will follow the recommended label dosing for adults with RA and
      PsA: 50 mg weekly (scheduled approximately 7 days apart).
    
  